Rimonabant (Acomplia) by Sanofi-Aventis, was licensed for use in the UK since June 2006 for the treatment of obesity.
However, adverts have claimed the drug can cut levels of potentially harmful cholesterol, fats and sugars in the blood to a greater extent than would be expected by weight loss alone. In theory, this should help to reduce the risk of developing type 2 diabetes and heart disease.
A report published in The Drug and Therapeutics Bulletin (DTB) on 30 May 2007 said there was no proof that the drug had any beneficial effects outside those expected by weight loss. The drug had not been effectively compared with other less expensive drug treatment for obesity.
The DTB authors said Orlistat (Xenical), costs less and approved for use in the NHS is the drug for obesity with the most evidence for efficacy and safety to date, and they have previously concluded that it is a reasonable option for obese patients where diet and exercise and/or behavioural measures alone have failed.
No comments:
Post a Comment